Course Director：刘宇扬

主席

主持人

讨论嘉宾

学习目标 Learning Objectives 1. 梳理2025年血脂领域核心研究突破与前沿进展，明确新型调脂策略、靶点药物及个体化血脂管理的创新方向与临床应用价值。 Sort out the core research breakthroughs and cutting-edge advances in the field of dyslipidemia in 2025, and clarify the innovative directions and clinical application values of novel lipid-lowering strategies, targeted drugs and individualized lipid management. 2. 剖析二十碳五烯酸乙酯在超高危心血管风险人群中的调脂机制与临床获益，明确其适用人群、用药指征及预后改善价值。 Analyze the lipid-regulating mechanism and clinical benefits of icosapent ethyl in patients with extremely high cardiovascular risk, and define its applicable population, medication indications and value in improving prognosis. 3. 解读PCSK9抑制剂及各类慢病调脂药物的剂型优势、给药优势与疗效差异，明确其在慢病心血管风险管理中的临床获益要点与精准应用边界。 Interpret the formulation advantages, administration merits and efficacy differences of PCSK9 inhibitors and various lipid-lowering agents for chronic diseases, and identify the key clinical benefits and precise application scope of such drugs in cardiovascular risk management for patients with chronic diseases

讨论定位： Discission Focus: 聚焦“超高危、慢病合并、个体化血脂异常患者如何精准调脂、最大化心血管获益”。重点讨论2025年血脂领域新型研究突破与前沿诊疗理念、二十碳五烯酸乙酯在超高危心血管风险人群中的个体化应用指征与预后价值、不同制剂类型PCSK9抑制剂及慢病调脂药物的技术优势与差异化临床获益等临床热点与应用难点。 This session centers on how to deliver precise lipid-lowering treatment and optimize cardiovascular benefits for patients with extremely high cardiovascular risk, combined chronic conditions and individualized dyslipidemia. It will delve into key clinical hot topics and practical challenges, including novel research breakthroughs and state-of-the-art diagnostic and therapeutic concepts in lipidology in 2025; individualized indications and prognostic value of icosapent ethyl among populations at extremely high cardiovascular risk; and the technical merits and distinct clinical benefits of PCSK9 inhibitors in diverse formulations as well as lipid-modifying medications for patients with chronic diseases.

建议讨论问题 Recommended Discussion Questions 1. 基于2025年血脂领域最新研究证据，超高危心血管风险人群的血脂管控目标是否需要进一步优化，如何实现个体化精准调脂干预？ Based on the latest research evidence in the field of lipidology in 2025, whether the lipid management targets for patients with extremely high cardiovascular risk need to be further optimized, and how to implement individualized precise lipid-lowering intervention? 2. 超高危心血管风险人群中，二十碳五烯酸乙酯的适用筛选标准、启动时机与长期用药疗程应如何界定，可最大化心血管获益？ Among patients with extremely high cardiovascular risk, how to define the screening criteria, initiation timing and long-term medication course of eicosapentaenoic acid ethyl ester to maximize cardiovascular benefits? 3. 结合新型制剂技术差异，不同剂型PCSK9抑制剂在慢病合并血脂异常人群中的疗效优势与适用场景有何区别，如何择优选择用药方案？ Combined with the differences in new formulation technologies, what are the differences in efficacy advantages and applicable scenarios of different PCSK9 inhibitor formulations in chronic disease patients with dyslipidemia, and how to optimize the medication selection? 4. 慢病合并血脂异常患者长期调脂治疗中，如何依托制剂技术优势平衡药物疗效、安全性与依从性，持续稳定实现心血管风险管控？ In the long-term lipid-lowering treatment of patients with chronic diseases complicated with dyslipidemia, how to balance drug efficacy, safety and compliance based on the advantages of formulation technology to steadily achieve long-term cardiovascular risk management? 5. 对于超高危、多慢病共病的复杂血脂异常人群，如何整合新型调脂药物与制剂技术优势，制定个体化、阶梯化的全程血脂管理策略？ For complex dyslipidemia patients with extremely high risk and multiple chronic comorbidities, how to integrate the advantages of new lipid-lowering drugs and formulation technologies to formulate individualized and stepwise whole-process lipid management strategies?

2025年血脂领域核心研究进展 2025 Core Research Advances in the Field of Lipidology

讨论

二十碳五烯酸乙酯在超高危心血管风险人群中的应用价值 The Clinical Value of Eicosapentaenoic Acid Ethyl Ester in Patients with Extremely High Cardiovascular Risk

讨论

基于制剂技术看PCSK9抑制剂和慢病管理药物临床获益 Clinical Benefits of PCSK9 Inhibitors and Chronic Disease Management Drugs from the Perspective of Formulation Technology

讨论